Oncodesign Precision Medicine Société anonyme Past Earnings Performance
Past criteria checks 0/6
Oncodesign Precision Medicine Société anonyme's earnings have been declining at an average annual rate of -3399.7%, while the Biotechs industry saw earnings growing at 13.4% annually. Revenues have been declining at an average rate of 79% per year.
Key information
-3,399.7%
Earnings growth rate
n/a
EPS growth rate
| Biotechs Industry Growth | 30.8% |
| Revenue growth rate | -79.0% |
| Return on equity | -219.2% |
| Net Margin | -465.0% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Oncodesign Precision Medicine Société anonyme makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 2 | -8 | 3 | 0 |
| 31 Dec 22 | 8 | 0 | 2 | 0 |
Quality Earnings: ALOPM is currently unprofitable.
Growing Profit Margin: ALOPM is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Unable to establish if ALOPM's year-on-year earnings growth rate was positive over the past 5 years as it has been trading publicly for less than 3 years.
Accelerating Growth: Unable to compare ALOPM's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ALOPM is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-1.3%).
Return on Equity
High ROE: ALOPM has a negative Return on Equity (-219.22%), as it is currently unprofitable.